“That’s why,” says Dr Naval Vikram Kishore, professor of medicine, Metabolic Research Group, AIIMS, “obesity has to be redefined for Indians (who have a higher fat mass than other populations) as it ...

Altimmune, Inc. (NASDAQ:ALT), a biopharmaceutical company with a market capitalization of $503.56 million focused on ...

Boston Scientific Corporation (NYSE:BSX), a leading player in the medical technology sector, has been making significant ...

Juvenile idiopathic arthritis is the most common chronic systemic disease associated with uveitis in childhood. Uveitis occurs in 11–22% of children with juvenile idiopathic arthritis.1 Due to the ...

We thank the authors for their interest in our paper, and their queries. In response to Yue Li and Guangsen Liu, given the current situation of malaria deaths and cases increasing in recent years,1 it ...

Following the Trump administration's DEI ban, the FDA's move to scrub webpages has ensnared many pages focused on ensuring diversity in drug trials.

Nearly half of patients with advanced ovarian cancer treated with first-line poly-ADP-ribose polymerase (PARP) inhibitors experienced recurrence in this real-world study, emphasizing the need for ...

Dr. Joao de Quevedo with UTHealth Houston shares what researchers found during a clinical trial for Spravato, the first FDA-approved nasal spray to treat depression.

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon confirm that.

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

Afinitor plus Somatuline showed an improved survival compared with Afinitor monotherapy in patients with gastroenteropancreatic neuroendocrine tumors.

The American College of Cardiology announced the late-breaking science lineup for its Scientific Session to be held March ...